Press ReleaseVALVOSOFT®, the first non-invasive treatment for severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave receives CE Marking Dec 4, 2025 READ MORE
Press ReleaseVALVOSOFT®, le premier traitement non invasif de la Sténose Aortique Sévère symptomatique (sSAS) développé par Cardiawave, obtient le marquage CE Dec 4, 2025 READ MORE
Press ReleaseCardiawave renforce son leadership avec la nomination de Jonathan Freeman, Président du CA Oct 30, 2025 READ MORE
Press ReleaseCardiawave Strengthens Leadership with Appointment of Jonathan Freeman as Board Chairman Oct 23, 2025 READ MORE
Events🚀 Cardiawave contributes to Medicen Paris Region’s “Regulatory by Design” event on Oct. 21! Oct 9, 2025 READ MORE
